All In Biotech

Drug Trial Radar · NCT06896916

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Aug 7, 2025

Primary completion

Mar 2036

Study completion Mar 2036

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. Approximately 135 adult participants with R/R MM will be enrolled in the study in approximately 50 sites worldwide. In phase 1 participants will receive escalating intravenous (IV) etentamig in combination with oral iberdomide. In phase 2 participants will receive IV etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side effects.

Conditions

  • Multiple Myeloma

Interventions

  • EtentamigDrug

    Intravenous (IV) Infusion

  • IberdomideDrug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Dose-Limiting Toxicities (DLT)s of Etentamig when given in Combination with Iberdomide in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)Time frame: Up to Approximately 56 Days
  2. Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 129 Months

Locations

27 sites in 7 countries. Site status is shown where the registry gives one.

  • Beverly Hills Cancer Center /ID# 266921

    Beverly Hills, California · Recruiting

  • Colorado Blood Cancer Institute /ID# 273751

    Denver, Colorado · Recruiting

  • Washington University /ID# 266972

    St Louis, Missouri · Recruiting

  • Rutgers Cancer Institute of New Jersey /ID# 266833

    New Brunswick, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282

    New York, New York · Recruiting

  • University Of North Carolina Health Care - Hillsborough Campus /ID# 278230

    Hillsborough, North Carolina · Recruiting

  • Swedish Medical Center - Seattle /ID# 268052

    Seattle, Washington · Recruiting

  • Blacktown Hospital /ID# 265983

    Blacktown, New South Wales, Australia · Recruiting

  • Wollongong Hospital /ID# 265625

    Wollongong, New South Wales, Australia · Recruiting

  • The Alfred Hospital /ID# 265981

    Melbourne, Victoria, Australia · Recruiting

  • Austin Hospital /ID# 265984

    Melbourne, Victoria, Australia · Recruiting

  • Sir Charles Gairdner Hospital /ID# 265985

    Nedlands, Western Australia, Australia · Recruiting

  • University Health Network_Princess Margaret Cancer Centre /ID# 275636

    Toronto, Ontario, Canada · Recruiting

  • Jewish General Hospital /ID# 267574

    Montreal, Quebec, Canada · Recruiting

  • Chu de Nice-Hopital Larchet Ii /Id# 266845

    Nice, Alpes-Maritimes, France · Recruiting

  • Hôpital La Timone /ID# 267053

    Marseille, Bouches-du-Rhone, France · Recruiting

  • Chu De Lille - Hopital Claude Huriez /ID# 270193

    Lille, Hauts-de-France, France · Recruiting

  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau /ID# 267694

    Tours, Indre-et-Loire, France · Recruiting

  • IUCT Oncopole /ID# 266391

    Toulouse, Occitanie, France · Recruiting

  • National Cancer Center Hospital East /ID# 268343

    Kashiwa-shi, Chiba, Japan · Recruiting

  • Kumamoto University Hospital /ID# 270530

    Kumamoto, Kumamoto, Japan · Recruiting

  • Dokkyo Medical University Hospital /ID# 271648

    Mibu, Tochigi, Japan · Recruiting

  • Nippon Medical School Hospital /ID# 270254

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • The Cancer Institute Hospital Of JFCR /ID# 268342

    Koto-ku, Tokyo, Japan · Recruiting

  • Universitair Medisch Centrum Utrecht /ID# 267660

    Utrecht, Netherlands · Recruiting

  • Amsterdam UMC, Location VUmc /ID# 267670

    Amsterdam, North Holland, Netherlands · Recruiting

  • Oslo Universitetssykehus Ulleval /ID# 275433

    Oslo, Norway · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.